Market Cap 13.25B
Revenue (ttm) 4.24B
Net Income (ttm) 32.61M
EPS (ttm) N/A
PE Ratio 100.68
Forward PE 14.40
Profit Margin 0.77%
Debt to Equity Ratio 0.00
Volume 2,340,000
Avg Vol 1,993,472
Day's Range N/A - N/A
Shares Out 193.57M
Stochastic %K 24%
Beta 0.67
Analysts Sell
Price Target $75.81

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a select...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 498 6700
Address:
1801 Augustine Cut-Off, Wilmington, United States
Nomorelies
Nomorelies Jun. 23 at 3:21 AM
$INCY Strong Hold!
0 · Reply
DonCorleone77
DonCorleone77 Jun. 21 at 1:39 PM
$INCY Incyte announces FDA extends review period for Opzelura sNDA The company states: "Incyte announced that the FDA has extended the review period for the supplemental New Drug Application, sNDA, for ruxolitinib cream, Opzelura, a topical Janus kinase inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis. The PDUFA action date has been extended by three months to September 19, 2025. The FDA extended the PDUFA action date to allow time to review additional chemistry, manufacturing and controls data on the 0.75% strength submitted by Incyte in response to a recent FDA information request." Steven Stein, M.D., Chief Medical Officer, Incyte stated: "We are confident in the potential of ruxolitinib cream to become an important non-steroidal, topical treatment option for pediatric patients with atopic dermatitis and we will continue to work closely with the FDA to ensure the Agency has all of the information needed to complete its review."
1 · Reply
Rifraf
Rifraf Jun. 19 at 1:21 PM
$INCY Surely this is a big deal but there don’t seem to be any posts about it. https://www.targetedonc.com/view/fda-approves-tafasitamab-in-r-r-follicular-lymphoma
0 · Reply
G101SPM
G101SPM Jun. 18 at 7:40 PM
$INCY $68.39 ask. BUY/NEW LONG POSITION carries SPM 88.01 tag to $75.00 in midterm.
0 · Reply
haileyanderson
haileyanderson Jun. 17 at 7:40 PM
0 · Reply
ZacksResearch
ZacksResearch Jun. 17 at 4:35 PM
$INCY surges 5.1% on global partnership news Incyte partners with $QGEN to develop a diagnostic panel for its MPN treatments, strengthening its precision medicine strategy. Year to date, INCY is up 3.1% vs. industry’s 0.9% decline. Discover how this deal might impact INCY's growth 👉 https://www.zacks.com/commentary/2507024/incyte-stock-rises-on-qiagen-deal-to-advance-blood-cancer-diagnostics?cid=sm-stocktwits-2-2507024-body&ADID=SYND_STOCKTWITS_TWEET_2_2507024_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 17 at 3:26 PM
$INCY pops on precision medicine play Stock is up 5.1% after locking in a global deal with QIAGEN to co-develop a companion diagnostic for its mutCALR-targeting therapy in blood cancers. Find out why this partnership could be a game changer 👉 https://www.zacks.com/stock/news/2507024/incyte-stock-rises-on-qiagen-deal-to-advance-blood-cancer-diagnostics?cid=sm-stocktwits-2-2507024-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2507024_TEASER
0 · Reply
Nomorelies
Nomorelies Jun. 17 at 1:20 PM
$ALKS $BBIO $INCY Strong!
0 · Reply
IN0V8
IN0V8 Jun. 16 at 8:45 PM
$INCY Buy Jefferies raises target price to $82 from $76 Stifel raises to buy from hold; raises PT to $107.00 from $75.00
0 · Reply
toInfinit3
toInfinit3 Jun. 16 at 7:55 PM
$INCY $GASS.X is the best choice
0 · Reply
Latest News on INCY
Incyte Says FDA Extended Review Period for Opzelura

Jun 20, 2025, 5:10 PM EDT - 2 days ago

Incyte Says FDA Extended Review Period for Opzelura


Incyte Lymphoma Treatment Gets FDA Approval

Jun 18, 2025, 4:12 PM EDT - 4 days ago

Incyte Lymphoma Treatment Gets FDA Approval


Incyte to Present at Upcoming Investor Conference

May 27, 2025, 8:00 AM EDT - 27 days ago

Incyte to Present at Upcoming Investor Conference


Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 12:53 PM EDT - 7 weeks ago

Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript


Incyte to Report First Quarter Financial Results

Apr 10, 2025, 8:00 AM EDT - 2 months ago

Incyte to Report First Quarter Financial Results


Incyte Is Today's Worst S&P 500 Stock. Here's Why.

Mar 17, 2025, 11:21 AM EDT - 3 months ago

Incyte Is Today's Worst S&P 500 Stock. Here's Why.


Incyte to Present at Upcoming Investor Conferences

Feb 18, 2025, 8:00 AM EST - 4 months ago

Incyte to Present at Upcoming Investor Conferences


Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Feb 11, 2025, 7:30 AM EST - 4 months ago

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025


Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript

Feb 10, 2025, 11:52 AM EST - 4 months ago

Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript


Incyte: Multiple Drug Launches Bode Well For Future Growth

Jan 11, 2025, 9:30 AM EST - 5 months ago

Incyte: Multiple Drug Launches Bode Well For Future Growth


Nomorelies
Nomorelies Jun. 23 at 3:21 AM
$INCY Strong Hold!
0 · Reply
DonCorleone77
DonCorleone77 Jun. 21 at 1:39 PM
$INCY Incyte announces FDA extends review period for Opzelura sNDA The company states: "Incyte announced that the FDA has extended the review period for the supplemental New Drug Application, sNDA, for ruxolitinib cream, Opzelura, a topical Janus kinase inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis. The PDUFA action date has been extended by three months to September 19, 2025. The FDA extended the PDUFA action date to allow time to review additional chemistry, manufacturing and controls data on the 0.75% strength submitted by Incyte in response to a recent FDA information request." Steven Stein, M.D., Chief Medical Officer, Incyte stated: "We are confident in the potential of ruxolitinib cream to become an important non-steroidal, topical treatment option for pediatric patients with atopic dermatitis and we will continue to work closely with the FDA to ensure the Agency has all of the information needed to complete its review."
1 · Reply
Rifraf
Rifraf Jun. 19 at 1:21 PM
$INCY Surely this is a big deal but there don’t seem to be any posts about it. https://www.targetedonc.com/view/fda-approves-tafasitamab-in-r-r-follicular-lymphoma
0 · Reply
G101SPM
G101SPM Jun. 18 at 7:40 PM
$INCY $68.39 ask. BUY/NEW LONG POSITION carries SPM 88.01 tag to $75.00 in midterm.
0 · Reply
haileyanderson
haileyanderson Jun. 17 at 7:40 PM
0 · Reply
ZacksResearch
ZacksResearch Jun. 17 at 4:35 PM
$INCY surges 5.1% on global partnership news Incyte partners with $QGEN to develop a diagnostic panel for its MPN treatments, strengthening its precision medicine strategy. Year to date, INCY is up 3.1% vs. industry’s 0.9% decline. Discover how this deal might impact INCY's growth 👉 https://www.zacks.com/commentary/2507024/incyte-stock-rises-on-qiagen-deal-to-advance-blood-cancer-diagnostics?cid=sm-stocktwits-2-2507024-body&ADID=SYND_STOCKTWITS_TWEET_2_2507024_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 17 at 3:26 PM
$INCY pops on precision medicine play Stock is up 5.1% after locking in a global deal with QIAGEN to co-develop a companion diagnostic for its mutCALR-targeting therapy in blood cancers. Find out why this partnership could be a game changer 👉 https://www.zacks.com/stock/news/2507024/incyte-stock-rises-on-qiagen-deal-to-advance-blood-cancer-diagnostics?cid=sm-stocktwits-2-2507024-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2507024_TEASER
0 · Reply
Nomorelies
Nomorelies Jun. 17 at 1:20 PM
$ALKS $BBIO $INCY Strong!
0 · Reply
IN0V8
IN0V8 Jun. 16 at 8:45 PM
$INCY Buy Jefferies raises target price to $82 from $76 Stifel raises to buy from hold; raises PT to $107.00 from $75.00
0 · Reply
toInfinit3
toInfinit3 Jun. 16 at 7:55 PM
$INCY $GASS.X is the best choice
0 · Reply
topstockalerts
topstockalerts Jun. 16 at 7:51 PM
$INCY not bad today.. 🏦📈🚨
0 · Reply
Nomorelies
Nomorelies Jun. 16 at 7:00 PM
$INCY https://www.marketbeat.com/instant-alerts/incyte-nasdaqincy-upgraded-by-stifel-nicolaus-to-buy-rating-2025-06-16/
0 · Reply
GoldenTradesCapital
GoldenTradesCapital Jun. 16 at 6:56 PM
Here is all of the latest news and updates about $INCY that you need to know ⬇️ • Incyte’s shares jumped ~8% after Phase II data showed strong results in mutant calreticulin (mCALR) blood cancers. • The drug INCA033989 demonstrated high response rates and biomarker normalization. • Upcoming FDA interactions and Phase III entry are key milestones in the coming months. Follow us to not miss any more important updates 🔱
0 · Reply
Nomorelies
Nomorelies Jun. 16 at 6:50 PM
$INCY I feel confident that a big pharma company with expiring patents on one or more of their blockbuster drugs, will take this company out.
0 · Reply
GoldenTradesCapital
GoldenTradesCapital Jun. 16 at 6:06 PM
Five biotech stocks catching attention this week 🧬 • $INCY – Breakthrough blood cancer data driving momentum • $VRTX – Gene editing pipeline gaining steam • $TXG – Single-cell innovation in research + diagnostics • $MRNA – New RSV vaccine entering commercialization phase • $CRSP – Riding CRISPR regulatory approvals Follow us for more daily alerts 🔱
0 · Reply
Nomorelies
Nomorelies Jun. 16 at 4:15 PM
$INCY The spread on the call options is crazy.
0 · Reply
TICKERTUTOR
TICKERTUTOR Jun. 16 at 2:55 PM
$INCY BAKER BROS JUST KEEP WINNING!!!!!!
0 · Reply
ZacksResearch
ZacksResearch Jun. 16 at 1:16 PM
$QGEN partners with $INCY — a game-changer for onco-hematology diagnostics? 🤔 ⚕️ New collab to develop NGS panels for blood cancer gene detection 📊 QGEN's earnings yield of 5% vs. industry’s -29.4% is impressive 🚀 Shares up 4.7% over the past year against the industry’s 12.7% decline Discover how this could boost QGEN's market sentiment 👉 https://www.zacks.com/commentary/2503105/qgen-stock-rises-in-after-market-following-partnership-with-incyte?cid=sm-stocktwits-2-2503105-body&ADID=SYND_STOCKTWITS_TWEET_2_2503105_BODY
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 16 at 11:58 AM
$INCY Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses
0 · Reply
briefingcom
briefingcom Jun. 16 at 11:55 AM
Gapping Up: $SATS +44.3% $PRTA +17.3% $JSPR +13.1% $INCY +10.5% $AIOT +9%
0 · Reply
Auphiliate
Auphiliate Jun. 16 at 10:25 AM
$AUPH M&A season! $INCY 👀
0 · Reply
DonCorleone77
DonCorleone77 Jun. 16 at 9:56 AM
$INCY Stifel upgrades Incyte to Buy after 'best-case scenario' data Stifel last night upgraded Incyte to Buy from Hold with a price target of $107, up from $75. This weekend's presentation of preliminary INCA033989 dose-escalation data in essential thrombocythemia patients "represents a best-case scenario," the analyst tells investors in a research note. The firm says INCA033989 yielded rapid and sustained clinical and molecular responses and, "most-impressively," clear biomarker-associated evidence of disease modification and restoration of normal hematopoiesis. Stifel is now adding $4.7B of peak INCA033989 sales to its model ahead of additional year-end data disclosures and an early fiscal 2026 Phase trial initiation. It believes the drug "provides a source of enthusiasm" which hasn't existed in the Incyte model since epacadostat.
0 · Reply